A roadmap for driving CAR T cells toward the oncogenic immunopeptidome. uri icon

Overview

abstract

  • A critical barrier to CAR T cell therapy is the paucity of target antigens that are broadly and stably expressed exclusively in tumors. In their comprehensive multi-omics and pre-clinical study, Yarmarkovich et al. provide proof of principle for the development and efficacy of peptide centric (PC)-CARs targeting the oncogenic immunopeptidome of neuroblastoma.

publication date

  • January 10, 2022

Research

keywords

  • Immunotherapy, Adoptive
  • Neuroblastoma

Identity

Scopus Document Identifier

  • 85123460867

Digital Object Identifier (DOI)

  • 10.1016/j.ccell.2021.12.011

PubMed ID

  • 35016027

Additional Document Info

volume

  • 40

issue

  • 1